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Abstract
Background We aimed to assess the cost effectiveness of intravitreal ranibizumab (Lucentis), aflibercept (Eylea) and beva-
cizumab (Avastin) for the treatment of macular oedema due to central retinal vein occlusion.
Methods We calculated costs and quality-adjusted life-years from the UK National Health Service and Personal Social Ser-
vices perspective. We performed a within-trial analysis using the efficacy, safety, resource use and health utility data from a 
randomised controlled trial (LEAVO) over 100 weeks. We built a discrete event simulation to model long-term outcomes. We 
estimated utilities using the Visual-Functioning Questionnaire-Utility Index, EQ-5D and EQ-5D with an additional vision 
question. We used standard UK costs sources for 2018/19 and a cost of £28 per bevacizumab injection. We discounted costs 
and quality-adjusted life-years at 3.5% annually.
Results Bevacizumab was the least costly intervention followed by ranibizumab and aflibercept in both the within-trial 
analysis (bevacizumab: £6292, ranibizumab: £13,014, aflibercept: £14,328) and long-term model (bevacizumab: £18,353, 
ranibizumab: £30,226, aflibercept: £35,026). Although LEAVO did not demonstrate bevacizumab to be non-inferior for 
the visual acuity primary outcome, the three interventions generated similar quality-adjusted life-years in both analyses. 
Bevacizumab was always the most cost-effective intervention at a threshold of £30,000 per quality-adjusted life-year, even 
using the list price of £243 per injection.
Conclusions Wider adoption of bevacizumab for the treatment of macular oedema due to central retinal vein occlusion 
could result in substantial savings to healthcare systems and deliver similar health-related quality of life. However, patients, 
funders and ophthalmologists should be fully aware that LEAVO could not demonstrate that bevacizumab is non-inferior 
to the licensed agents.
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Key Points for Decision Makers 
Although bevacizumab was not non-inferior to ranibi-
zumab and aflibercept in LEAVO, the three interventions 
generate similar quality-adjusted life-years.
Bevacizumab is always the most cost-effective interven-
tion at £20,000–£30,000 per quality-adjusted life-year.
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1 Introduction
Macular oedema (MO) due to central retinal vein occlu-
sion (CRVO) is associated with vision-related quality-of-
life impairment and costs to healthcare systems and socie-
ties more broadly [1, 2]. The annual incidence of visual 
impairment from MO due to CRVO in England and Wales 
is estimated to be 5700 [3–6]. Central retinal vein occlu-
sion may be ischaemic or non-ischaemic, with ischaemic 
CRVO being associated with further complications such as 
neovascular glaucoma [7]. The prevalence and incidence 
of CRVO increase with age [3].
Aflibercept (Eylea) [2  mg/0.05  mL (Bayer Pharma 
AG)], ranibizumab (Lucentis) [0.5 mg/0.05 mL (Novartis)] 
and bevacizumab (Avastin) [1.25 mg/0.05 mL (Roche)] are 
anti-vascular endothelial growth factor inhibitors given by 
a repeated intravitreal injection to treat MO due to CRVO. 
Aflibercept and ranibizumab are licensed for this indica-
tion [8, 9] with list prices per injection of £816 and £551, 
respectively [10, 11]. The National Institute for Health 
and Care Excellence (NICE) recommends ranibizumab 
and aflibercept (each with a discount on the list price) as 
treatments for MO due to CRVO [12, 13].
Bevacizumab, currently available off-label for this indi-
cation, costs £243 per large vial, or £28 per injection when 
separated from the vial into pre-filled syringes [14, 15]. 
Because of the potential for cost savings, bevacizumab 
has been proposed as an alternative intervention for MO 
due to CRVO [1]. The Court of Appeal recently ruled that 
offering off-label bevacizumab to National Health Service 
(NHS) patients with wet age-related macular degeneration 
is lawful [16]. Our aim was to compare the cost effec-
tiveness of bevacizumab, ranibizumab and aflibercept for 
treating MO due to CRVO.
2  Methods
2.1  LEAVO Study
LEAVO was a multicentre, randomised non-inferiority 
clinical trial of 463 (non-ischaemic: 406, ischaemic: 56, 
missing ischaemic status: 1) participants conducted in 44 
UK NHS hospitals, comparing ranibizumab, aflibercept 
and bevacizumab for the treatment of MO due to CRVO 
[17, 18]. The primary outcome was change in best-cor-
rected visual acuity (BCVA) Early Treatment Diabetic 
Retinopathy Study letter score (number of letters read on 
a chart at a fixed distance) from baseline to 100 weeks. 
The clinical effectiveness analysis was unable to demon-
strate that bevacizumab was non-inferior (non-inferiority 
limit defined as − 5 Early Treatment Diabetic Retin-
opathy Study letters) to ranibizumab in the intention-to-
treat (ITT) population (adjusted mean BCVA difference 
− 1.73 letters; 95% confidence interval [CI] − 6.12 to 
2.67; p = 0.071). Aflibercept was non-inferior to ranibi-
zumab in the ITT population (adjusted mean BCVA dif-
ference 2.23 letters; 95% CI − 2.17 to 6.63; p = 0.0006) 
but not superior. A post hoc analysis was unable to show 
that bevacizumab was non-inferior to aflibercept in the 
ITT population (adjusted mean BCVA difference − 3.96 
letters; 95% CI − 8.34 to 0.42; p = 0.32). The per-protocol 
results were similar [18].
2.2  Economic Evaluation Overview
We conducted a within-trial analysis using individual 
patient-level data from LEAVO to calculate the costs 
and quality-adjusted life-years (QALYs) over 100 weeks 
and a decision analytic model to calculate the costs and 
QALYs over the entire lifetime horizon [19]. We consid-
ered the NHS and Personal Social Services perspective, 
in accordance with the NICE Methods Guide [20]. We 
discounted costs and QALYs at 3.5% annually [20]. We 
compared results using an incremental analysis, as pre-
ferred by NICE [20]. We calculated the probability that 
bevacizumab was the most cost-effective intervention 
at £20,000 and £30,000 per QALY. The methods for the 
health economic analysis were pre-specified prior to the 
database lock [19].
2.3  Data Analysis
2.3.1  Within‑Trial
We used an ITT analysis, including all the participants 
randomised to each treatment group. When a participant 
withdrew from the study, and a withdrawal appointment 
occurred, we assigned their cost and utility data to the near-
est visit, all subsequent costs were set to zero and recorded 
utilities as missing. If there was no withdrawal appointment, 
subsequent costs and utilities were assumed to be missing at 
random. We used multiple imputation using chained equa-
tions with predictive mean matching to impute missing val-
ues of costs, QALYs and baseline covariates to account for 
missing data [21].
We used a seemingly unrelated regression model to esti-
mate the difference in mean total costs and QALYs between 
treatment arms, taking into account correlation [22, 23]. The 
regression equation for total costs included the randomi-
sation arm. The regression equation for QALY included 
the randomisation arm and baseline utility to control for 
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imbalances between treatment arms [22, 23]. In the model, 
we assumed a normal distribution for both costs and QALYs. 
We calculated marginal effects in each treatment arm using 
the seemingly unrelated regression without adjusting for 
baseline utility.
2.3.2  Economic Model
We constructed a discrete event simulation to model the path-
way of individual patients through a set of events from the 
beginning of LEAVO until death, according to the time sam-
pled for each event [24]. The advantages of a discrete event 
simulation in this application were:
1. Health states were not required, thus each individual 
patient’s visual acuity could be tracked over time on a 
continuous scale.
2. The study eye and non-study eye could be modelled 
separately.
3. Each patient’s history could be tracked, to allow 
incorporation of the treatment continuation rule (see 
Sect. 2.4.2).
4. The follow-up visit times could be modelled using the 
treatment continuation rule and LEAVO milestone visit 
schedule (see Sect. 2.4.2).
5. Individual patients could have different baseline charac-
teristics to incorporate heterogeneity.
Events in the model were visits to an ophthalmolo-
gist (to assess and administer injections), ocular adverse 
events, withdrawal, new-onset MO in the non-study eye 
and death. We assigned sampled times to different events 
each time a patient was simulated and updated them as 
necessary (see Fig.  1), allowing the patient’s history 
to influence when and whether future events occurred. 
Simulated patients moved to the next chronological event, 
where their visual acuity, costs and utility were updated. 
We assumed that the baseline characteristics of LEAVO 
patients (age, sex and visual acuity) were representative 
of the MO due to CRVO population in England, and ran-
domly assigned an entire patient profile for simulated 
patients to preserve the relationship between baseline 
characteristics. We included development of MO in the 
non-study eye at an annual rate of 0.009 per year (calcu-
lated by fitting an exponential distribution to the eight 
LEAVO patients who developed MO in their non-study 
eye) and assumed that patients would receive the same 
intervention in both eyes. We simulated 7000 patients for 
each intervention, as the total costs and QALYs had sta-
bilised by this point. A full list of input parameters and 
stabilisation graphs are provided in the Electronic Sup-
plementary Material (ESM).
2.4  Data Sources
2.4.1  Health Utilities
LEAVO included three measures of health-related quality 
of life (HRQoL) at each visit: the Visual Functioning Ques-
tionnaire-Utility Index (VFQ-UI) [25], the five-level EQ-5D 
(a generic measure used across disease areas and preferred 
by NICE) [20] and the EQ-5D with an additional vision 
dimension (EQ-5D V) [26]. These measures are used to esti-
mate “utility”, where 1 is full health and 0 is equivalent to 
death, and can then be combined with life-years to calculate 
QALYs. In the within-trial analysis, we used the utilities at 
each visit for each patient to calculate total QALYs using 
linear interpolation. As the model predicted BCVA beyond 
the trial period (see Sect. 2.4.8), to convert BCVA to utility 
in the economic model, we developed statistical models that 
predicted HRQoL as a function of BCVA in both eyes, age 
and sex [27]. As specified in the Health Economics Analysis 
Plan prior to conducting the study [19], we used VFQ-UI 
in the base case to model utility as EQ-5D has been shown 
to perform poorly in eye conditions [28], and EQ-5D and 
EQ-5D V in scenario analyses.
2.4.2  Intervention Costs
In LEAVO, the treatment regime included mandated injec-
tions of ranibizumab, aflibercept or bevacizumab at weeks 0, 
4, 8 and 12 followed by visits at weeks 16 and 20 when they 
could receive an injection if their study eye BCVA was ≤ 83 
letters, and they met at least one of the retreatment criteria:
• Decrease in visual acuity of ≥ 6 letters between the previ-
ous and current visit and an increase in central subfield 
thickness, or
• Increase in visual acuity of ≥ 6 letters between the previ-
ous and current visit, or
• Central subfield thickness (CST) > 320 µm, or
• CST increase of > 50 µm from the lowest previous visit.
The retreatment criteria were applied between weeks 24 and 
96. If a patient did not meet retreatment criteria at three consec-
utive visits, the visit interval was increased from 4 to 8 weeks. 
In the within-trial analysis, costs associated with delivering the 
intervention included drug costs, appointment costs and test 
costs including: optical coherence tomography, colour fundus 
photography and fundus fluorescein angiography.
The model included the mandated injections for all 
patients and simulated the same retreatment criteria and 
included treatment withdrawal modelled separately for 
the three interventions (see ESM). We sought advice from 
five clinicians (PH, SS, YY, AL, MW) and guidance from 
the Royal College of Ophthalmologists [3] for modelling 
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ophthalmologist visits beyond the trial period and assumed 
that after 100 weeks:
• Patients who had not had injections after 52 weeks in 
LEAVO no longer received injections or visited the 
ophthalmologist to be assessed.
• Between 100 weeks and 5 years, we applied the same 
retreatment criteria as in LEAVO, but increased the 
time between visits to 12 weeks, and assumed that 
patients who were not treated at three consecutive vis-
its no longer received injections or visited the ophthal-
mologist to be assessed.
Fig. 1  Model diagram. BCVA best-corrected visual acuity, CST central subfield thickness, OCT optical coherence 5 tomography, QALY quality-
adjusted life-year
917 Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for Macular Oedema 
• Beyond 5 years, we assumed that patients no longer 
received injections but had three follow-up visits with 
the ophthalmologist, 12 weeks apart. We included the 
costs of the injections and the costs of visits to the oph-
thalmologist.
2.4.3  Resource Use
We included resource use costs associated with MO due 
to CRVO, collected in LEAVO using a specially developed 
resource use questionnaire at baseline, 12, 24, 52, 76 and 
100 weeks (given in the ESM) in the trial-based analysis. 
We estimated linear regression models using ordinary least 
squares to predict the number of appointments with differ-
ent healthcare professionals as a function of BCVA in the 
worse-seeing eye, and used these in the model to extrapolate 
healthcare resource use beyond the trial period.
2.4.4  Unit Costs
The list prices for ranibizumab (£551 per injection) and 
aflibercept (£816 per injection) were from the British 
National Formulary [10, 11]. In LEAVO, bevacizumab vials 
were compounded into pre-filled syringes at the Royal Liver-
pool and Broadgreen University Hospitals Pharmacy Asep-
tic Unit, costing £28 per injection [15], which the Medicines 
and Healthcare products Regulatory Agency clarified does 
not create an unlicensed medicine [29]. We assumed the cost 
per injection includes any costs associated with compound-
ing the drug, such as staff time and storage costs. We used 
the list price of £243 for bevacizumab in a scenario analysis, 
equivalent to assuming a vial can only be used for a single 
injection with the remainder of the vial wasted [14]. We used 
2018 NHS Reference Costs and Unit Costs of Health and 
Social Care for resource use where possible, uplifting older 
costs to 2018 using hospital and community health services 
indices [30, 31]. Unit costs are shown in Table 1.
2.4.5  Blindness Costs
We included a cost of blindness, which is made up of one-off 
costs for blind registration for all patients, and low vision 
aids and low vision rehabilitation for a proportion of patients 
(33% and 11%) in the model and trial-based analysis. The 
model additionally included annual costs for proportions 
of patients requiring community care (6%), residential care 
(30%), treatment for depression (39%) and hip replacement 
(5%) [32]. Blindness costs were sourced using NHS Refer-
ence Costs and Unit Costs of Health and Social Care for 
resource use [30, 31] and the resource use from published 
economic evaluations in ophthalmic indications [32] as the 
duration of LEAVO was not long enough to collect reliable 
estimates for blindness costs. The model included blindness 
costs for patients whose BCVA in both eyes was below 35 
letters (rare in CRVO) [33], consistent with previous models 
in MO [12, 13]. The within-trial analysis included costs for 
partial visual impairment for patients whose BCVA in both 
eyes was less than or equal to 58 letters (≤ 6/24) in both eyes 
and severe visual impairment if their BCVA was less than 
or equal to 19 letters (< 3/60) in both eyes. The within-trial 
analysis aimed to reflect the highest possible costs associated 
with blindness, assuming the same proportion of partially 
sighted patients would register as blind and incur the same 
costs as those who are severely sight impaired.
2.4.6  Ocular Adverse Events
We included costs for ocular adverse events in the within-
trial analysis using data from the resource use questionnaire, 
case report forms and concomitant procedure and medica-
tion logs. In the model, we included ophthalmic adverse 
events based on the frequency in LEAVO using an average 
NHS cost (see ESM) [24]. Simulated patients could have 
more than one ophthalmic adverse event.
2.4.7  Mortality
In the within-trial analysis, when a patient died, we set their 
utility scores at all subsequent visits to zero, and assumed 
that half the costs expected between the previous and next 
scheduled visit were incurred. This was to reflect the fact the 
participants may have incurred costs between visits before 
they died. In the model, we incorporated mortality by apply-
ing age- and sex-specific standardised mortality ratios to UK 
lifetable data to reflect the additional mortality associated 
with CRVO [34, 35]. Modelled patients who died no longer 
incurred costs or QALYs. None of the LEAVO participants 
died as a consequence of the treatments and thus there was 
no loss of life costs incurred.
2.4.8  Visual Acuity
We fitted equations to LEAVO data to predict BCVA for the 
first 100 weeks of starting treatment as a function of base-
line BCVA, age, intervention, number of injections, the time 
since the most recent injection and time-variant covariates at 
weeks 12, 24, 52 and 76 weeks (see Appendix in the ESM). 
Beyond 76 weeks, log-likelihood tests indicated models 
without the time-varying covariates should not be rejected 
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Table 1  Unit costs
Parameter Used in within-
trial analysis or 
model
Mean (standard error) Distribu-
tion used in 
model
Reference (mean) Reference (standard error)
Ranibizumab injection Both £551.00 N/A BNF 2019 [5] N/A
Aflibercept injection Both £816.00 N/A BNF 2019 [6] N/A
Bevacizumab injection Both £28.00 N/A Judicial review (2018) 
[10]
N/A
Central subfield thickness 
examination
Both £108.21 (£1.70) Gamma NHS Improvement (2018) 
[26]
NHS codes BZ87A
Quartile data of the NHS 
codes
Department of Health 
(2017) [41]First visit to ophthalmolo-
gist
Both £140.04 (£9.91) Gamma NHS Improvement (2018) 
[26]
NHS codes WF02B
Follow-up visit to oph-
thalmologist



















Accident and emergency 
visit
Both £160.23 (£9.34) Gamma NHS Improvement (2018) 
[26]
Weighted average for 
NHS codes VB01Z to 
VB11Z
Quartile data of the NHS 
codes (weighted)
Department of Health 
(2017) [41]
Ocular accident and emer-
gency visit
Both £118.02 (£2.67) Gamma NHS Improvement (2018) 
[26]
NHS codes WF01B
Eye consultant visit Both £95.13 (£1.85) Gamma NHS Improvement (2018) 
[26]
NHS codes WF01A
Ophthalmologist call Both £28.20 (£4) Gamma NHS Improvement (2018) 
[26]
NHS codes WF01D
Optometrist/optician visit Both £76.50 (£10.5) Gamma NHS Improvement (2018) 
[26]
NHS codes WF01B
Low vision appointment 
visit
Both £153.00 N/A Estimated to be double the visit cost of an optom-
etrist/optician to reflect additional complexity (on 
clinician advice)
General practitioner visit Both £37.40 (£3.74) Gamma Curtis and Burns (2018) 
[25]
10% assumption around the 
meanPractice nurse visit Both £17.79 (£1.78) Gamma
General practitioner call Both £28.00 (£2.8) Gamma
Community care (annual) Model £10,060.95 (£1006.10) Gamma Curtis and Burns (2018) 
[25]
10% assumption around 
mean
Hip replacement (annual) Model £4170.00 (£417.00) Gamma NHS Improvement (2018) 
[24]
Code HT14C
10% assumption around 
mean
Low vision aids (one-off) Both £194.41 (£19.44) Gamma Meads (2003), Curtis and 
Burns (2018)
10% assumption around 
mean
Low vision rehabilitation 
(one-off)
Model £153 Gamma Estimated to be double the visit cost of an optom-
etrist/optician
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and can therefore be used to extrapolate beyond 100 weeks. 
Similar equations to predict CST were fitted as required 
for the retreatment criteria (see ESM). For untreated eyes 
(including non-study eyes, and those that withdrew from 
or discontinued treatment), we modelled changes in BCVA 
annually using data from the Beaver Dam study [36].
2.5  Base‑Case and Scenario Analyses
2.5.1  Within‑Trial
For the VFQ-UI base case, we used a parametric approach 
to address the uncertainty around the cost-utility analyses 
estimates. We calculated the probability of each treatment 
being the most cost effective by sampling the mean costs and 
QALYs from a bivariate normal distribution. We addition-
ally conducted a complete case analysis, excluding patients 
with any missing data and a 52-week analysis using imputed 
data up to the 52-week milestone visit.
2.5.2  Economic Model
We estimated the percentage discount required for afliber-
cept and ranibizumab to be cost effective compared to 
bevacizumab at the £20,000 per QALY threshold. We addi-
tionally considered a 100-week time horizon for validation 
against the within-trial analysis.
For the base-case and scenario analyses, we undertook a 
probabilistic sensitivity analysis, simultaneously sampling 
all uncertain parameters from their distributions (see Appen-
dix in the ESM). We presented means and 95% CIs for total 
and incremental costs and QALYs and the mean ICER. We 
ran 500 simulations, a number sufficient to avoid decision 
uncertainty.
3  Results
3.1  Within‑Trial Analysis
3.1.1  Base Case
A total of 462 participants were included in the within-
trial analysis (one participant was excluded as no data were 
provided). Bevacizumab was the least costly intervention 
(£6292), followed by ranibizumab (£13,014) and afliber-
cept (£14,328). Bevacizumab was statistically significantly 
cheaper than ranibizumab and aflibercept (Table 2).
Utility scores are shown in Fig. 2 with the number of 
participants in each arm providing data at each milestone 
visit summarised below each graph. Using VFQ-UI, beva-
cizumab led to the most QALYs (1.666) over the 100-
week trial period, aflibercept the second most (1.651) and 
ranibizumab the least (1.627). There was no statistically 
significant difference in the QALYs for bevacizumab 
compared to ranibizumab and aflibercept. Bevacizumab 
dominated ranibizumab and aflibercept (ranibizumab and 
aflibercept were both more costly and less effective com-
pared with bevacizumab). The probability that bevaci-
zumab was the most cost-effective intervention compared 
to aflibercept and ranibizumab was 100% at £30,000 per 
QALY (Table 2).
3.1.2  Scenario Analyses
The complete case analysis and 52-week scenario using 
VFQ-UI led to the same findings as the base case. There 
was no statistically significant difference in QALYs 
(adjusted for the baseline utility score) between the three 
interventions, but bevacizumab was statistically sig-
nificantly cheaper and thus dominated ranibizumab and 
aflibercept (Table 2).
Table 1  (continued)
Parameter Used in within-
trial analysis or 
model
Mean (standard error) Distribu-
tion used in 
model
Reference (mean) Reference (standard error)
Residential care (annual) Model £6000.80 (£600.08) Gamma Curtis and Burns (2018) 
[25]
10% assumption around 
mean
Treatment for depression 
(annual)




Both £60.50 (£6.05) Gamma Curtis and Burns (2018) 
[25]
10% assumption around 
mean
Adverse event Model £317.96 (£28.62) Gamma NHS Improvement (2018) 
[26]
Weighted variance from 
NHS reference costs
BNF British National Formulary, N/A not applicable, NHS National Health Service, NICE National Institute for Health and Care Excellence
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Using EQ-5D and EQ-5D V, ranibizumab led to the few-
est QALYs followed by bevacizumab and aflibercept, but 
the difference in QALYs was not statistically significant. In 
both cases, bevacizumab dominated ranibizumab, and the 
ICER for aflibercept vs ranibizumab was considerably above 
£30,000 per QALY (Table 2). Using a list price of £243 
for bevacizumab, the total bevacizumab costs increased to 
£8933, but bevacizumab was still statistically significantly 
cheaper and continued to dominate ranibizumab and afliber-
cept (Table 2).
3.2  Economic Model
3.2.1  Base Case
The base-case economic model analysis considered the 
long-term cost effectiveness of the treatments beyond the 
end of the LEAVO trial (mean 15.6 years). Bevacizumab 
was the least costly intervention (£18,353), followed by 
ranibizumab (£30,226) and aflibercept (£35,026). Bevaci-
zumab was statistically significantly cheaper than ranibi-
zumab and aflibercept (Table 3).
Using VFQ-UI, bevacizumab provided the most QALYs 
(9.678), followed by ranibizumab (9.635), and aflibercept 
(9.569)—equivalent to 0.5 and 1.3 additional months at 
full health. Bevacizumab led to statistically significantly 
more QALYs. Therefore, bevacizumab dominated ranibi-
zumab and aflibercept. The probability that bevacizumab 
was the most cost-effective intervention was 98.6% at 
£20,000 per QALY.
3.2.2  Scenario Analyses
Using EQ-5D, bevacizumab provided the fewest QALYs fol-
lowed by ranibizumab and aflibercept (difference equivalent to 
less than 1 month at full health). We compared ranibizumab to 
bevacizumab, and aflibercept to ranibizumab because an incre-
mental analysis compares each intervention to the next most 
Table 2  Within-trial analysis: base-case and scenario analysis results
BNF British National Formulary, CI confidence interval, EQ-5D EuroQol-5 Dimension, EQ-5D V EuroQol-5 Dimension with Vision bolt-on, 
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, SD standard deviation
a Adjusted for baseline utility score
Total (SD) Incremental (95% CI) ICER (£)
Costs (£) QALYs Costs (£) QALYsa
Base-case analysis
Bevacizumab 6292 (5759–6824) 1.666 (1.629–1.704) – –
Ranibizumab 13,014 (12,444–13,584) 1.627 (1.588–1.666) 6734 (5970–7498) − 0.019 (− 0.066 to 0.028) Dominated
Aflibercept 14,328 (13,731–14,925) 1.651 (1.613–1.690) 7984 (7209–8759) − 0.015 (− 0.062 to 0.032) Dominated
Scenario analysis: EQ-5D for utilities
Bevacizumab 6273 (5738–6808) 1.535 (1.476–1.595) – –
Ranibizumab 13,068 (12,493–13,643) 1.513 (1.454–1.572) 6769 (5987–7550) − 0.010 (− 0.071 to 0.050) Dominated
Aflibercept 14,271 (13,661–14,882) 1.560 (1.499–1.619) 8035 (7246–8824) 0.008 (− 0.053 to 0.068) 1,041,476
Scenario analysis: EQ-5D V for utilities
Bevacizumab 6268 (5736–6800) 1.500 (1.441–1.5591) – –
Ranibizumab 13,000 (12,421–13,579) 1.472 (1.414–1.530) 6748 (5948–7547) − 0.035 (− 0.117 to 0.048) Dominated
Aflibercept 14,273 (13,684–14,861) 1.516 (1.455–1.577) 8012 (7232–8793) 0.003 (− 0.084 to 0.090) 2,483,943
Complete case analysis
Bevacizumab 6459 (5587–7332) 1.651 (1.603–1.699)
Ranibizumab 12,608 (11,756–13,461) 1.656 (1.609–1.703) 6149 (4929–7369) 0.007 (− 0.046 to 0.060) 890,736
Aflibercept 14,013 (13,167–14,859) 1.691 (1.644–1.737) 1405 (204–2606) 0.011 (− 0.041 to 0.063) 130,020
Scenario analysis: 52 weeks
Bevacizumab 3621 (3302–3940) 0.884 (0.866–0.903) – –
Ranibizumab 8164 (7822–8506) 0.865 (0.845–0.884) 4565 (4085–5045) − 0.008 (− 0.030 to 0.014) Dominated
Aflibercept 9214 (8860–9568) 0.880 (0.861–0.899) 5560 (5082–6039) − 0.004 (− 0.026 to 0.017) Dominated
Scenario analysis: bevacizumab list price from BNF (£243)
Bevacizumab 8933 (8384–9482) 1.666 (1.629–1.704) – –
Ranibizumab 13,014 (12,433–13,595) 1.627 (1.588–1.666) 4093 (3281–4904) −0.019 (− 0.066 to 0.028) Dominated
Aflibercept 14,328 (13,721–14,935) 1.651 (1.613–1.690) 5342 (4552–6133) − 0.015 (− 0.062 to 0.032) Dominated
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Fig. 2  Utility scores over 
100 weeks. EQ5D3L EQ-5D 
three level, EQ5DV EQ-5D with 
vision bolt-on, VFQ-UI Visual 
Functioning Questionnaire-
Utility Index
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effective (excluding dominated interventions). The 95% CIs 
for the incremental QALYs for ranibizumab vs bevacizumab 
and aflibercept vs ranibizumab contained only positive values. 
Using EQ-5D V, the results suggested the same numerical trend 
as EQ-5D, but ranibizumab was not statistically significantly 
better. For both EQ-5D and EQ-5D V, ranibizumab was extend-
edly dominated (dominated by a combination of aflibercept and 
bevacizumab) and the ICERs for aflibercept vs bevacizumab 
were over £30,000 per QALY. The probability that bevaci-
zumab was the most cost-effective intervention was 99.7% (EQ-
5D) and 98.0% (EQ-5D V) at £20,000 per QALY and 99.0% 
(EQ-5D) and 97.1% (EQ-5D V) at £30,000 per QALY.
Using a list price of £243 for bevacizumab, the total 
costs for bevacizumab increased to £23,530 (95% CI 
£22,884–£24,176). In this scenario, the incremental costs for 
ranibizumab vs bevacizumab decreased, but bevacizumab 
continued to dominate both ranibizumab and aflibercept. 
The probability that bevacizumab was the most cost-effec-
tive intervention was 94.7% at £20,000 per QALY and 91.3% 
at £30,000 per QALY (Table 3).
3.2.3  100‑Week Time Horizon
Using a 100-week time horizon, bevacizumab and ranibi-
zumab generated almost the same number of QALYs 
(1.641), and aflibercept generated slightly more QALYs 
(1.646) (Table 3). Bevacizumab remained the least costly 
intervention (£6349), followed by ranibizumab (£15,254) 
and aflibercept (£18,844). Ranibizumab was extendedly 
dominated and the ICER for aflibercept vs bevacizumab 
was above £30,000 per QALY and bevacizumab had 100% 
probability of being the most cost-effective intervention at 
£20,000 and £30,000 per QALY.
Table 3  Model-based analysis: base-case and scenario analysis results
BNF British National Formulary, CI confidence interval, EQ-5D EuroQol-5 Dimension, EQ-5D V EuroQol-5 Dimension with Vision bolt-on, 
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year
a Adjusted for baseline utility score
Total (95% CI) Incremental (95% CI)a ICER (£)
Costs (£) QALYs Costs (£) QALYs QALYs
Base-case analysis
Bevacizumab 18,353 (17,782–18,925) 9.678 (9.572–9.785)
Ranibizumab 30,226 (29,386–31,066) 9.635 (9.512–9.757) 11,873 (11,458–12,288) − 0.044 (− 0.074 to 
− 0.013)
Dominated
Aflibercept 35,026 (33,990–36,062) 9.569 (9.429–9.710) 16,673 (16,036–17,310) − 0.109 (− 0.161 to 
− 0.057)
Dominated
Scenario analysis: EQ-5D for utilities
Bevacizumab 18,353 (17.782–18,925) 8.782 (8.740–8.823)
Ranibizumab 30,226 (29,386–31,066) 8.795 (8.754–8.836) 11,873 (11,458–12,288) 0.013 (0.008–0.018) 908,532
Aflibercept 35,026 (33,990–36,062) 8.832 (8.790–8.874) 4800 (4445–5154) vs 
ranibizumab




Scenario analysis: EQ-5D V for utilities
Bevacizumab 18,353 (17.782–18,925) 8.346 (8.282–8.410)
Ranibizumab 30,226 (29,386–31,066) 8.351 (8.283–8.419) 11,873 (11,458–12,288) 0.005 (− 0.007 to 0.017) 2,491,676
Aflibercept 35,026 (33,990–36,062) 8.369 (8.289–8.449) 4800 (4445–5154) vs 
ranibizumab




Scenario analysis: 100-week time horizon
Bevacizumab 6349 (6293–6405) 1.641 (1.631–1.651)
Ranibizumab 15,254 (14,962–15,545) 1.641 (1.631–1.651) 8905 (8650–9161) 0.000 (− 0.000 to 0.001) 34,067,841
Aflibercept 18,844 (18,438–19,249) 1.646 (1.636–1.655) 3590 (3400–3780) 0.005 (0.004–0.005) 793,348 (vs ranibizumab)
2,610,554 (vs bevaci-
zumab)
Scenario analysis: bevacizumab list price from BNF (£243)
Bevacizumab 23,530 (22,884–24,176) 9.678 (9.572–9.785)
Ranibizumab 30,226 (29,386–31,066) 9.635 (9.512–9.757) 6696 (6400–6992) − 0.044 (− 0.074 to 
− 0.013)
Dominated
Aflibercept 35,026 (33,990–36,062) 9.569 (9.429–9.710) 11,496 (10,961–12,030) − 0.109 (− 0.161 to 
− 0.057)
Dominated
923 Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for Macular Oedema 
3.2.4  Disaggregated Costs
The cost breakdown per each intervention is shown in 
Table 4. To generate comparable intervention costs, assum-
ing a cost of £28 per bevacizumab injection would require 
a discount of at least 95% on the list price of aflibercept 
and ranibizumab. Whether this would lead them to be cost 
effective at £30,000 per QALY would depend on the utility 
measure used. If bevacizumab were assumed to cost £243 
per injection, aflibercept and ranibizumab would have com-
parable costs with a discount of 63% and 53% applied to the 
list price respectively.
4  Discussion
4.1  Principal Findings
Based on our assumptions and models, we found that 
bevacizumab was the most cost-effective intervention for 
the treatment of MO due to CRVO at £30,000 per QALY. 
Our findings were consistent between the model-based and 
within-trial analyses and robust to scenario analyses using 
alternative assumptions. This finding would change only if 
substantial discounts were offered on the price of ranibi-
zumab or aflibercept. The inclusion of three utility measures 
in LEAVO allowed us to consider scenarios using vision-
specific or generic measures of health. We found that the 
VFQ-UI led to more total QALYs for each intervention 
but the incremental QALYs were similar using the three 
measures.
We found that bevacizumab and ranibizumab did not 
generate significantly different QALYs; however, LEAVO 
found that bevacizumab was not non-inferior to ranibi-
zumab when analysing the change in BCVA in the study 
eye [18]. This difference between QALY and visual acuity 
outcomes may be because patients’ overall sight is deter-
mined by their visual acuity in both eyes (the better and 
worse seeing eyes and the interaction between them), and 
thus HRQoL may not closely relate to assessment of vis-
ual acuity in one eye alone. Treatment becomes a difficult 
issue as clinicians and patients typically wish to optimise 
visual acuity in the affected eye, although this may not 
significantly alter the patient’s overall health and quality 
of life. Furthermore, treatment may change which eye is 
the better-seeing eye (if the worse-seeing eye is treated 
and improves to an extent that it is better than the original 
better-seeing eye), which will affect estimated utility in 
our models as the mappings use different coefficients for 
the better-seeing eye and worse-seeing eye.
Our findings suggest that to maximise health within 
a fixed general NHS healthcare budget, NHS clinicians 
in England could consider using bevacizumab instead 
of aflibercept or ranibizumab to treat MO due to CRVO. 
Whether this would lead to a small increase or decrease in 
health depends on the utility measure used. Such decisions 
may be considered controversial, particularly where the will-
ingness to accept health losses differs from the willingness 
to pay for health gains. If aflibercept and ranibizumab were 
new interventions for treating MO due to CRVO, and beva-
cizumab was established standard care, it would be highly 
unlikely that NICE would consider aflibercept and ranibi-
zumab cost-effective interventions at their list prices. Treat-
ment with bevacizumab saves £5560 per year compared with 
aflibercept or £4545 compared with ranibizumab (see the 
ESM). If the estimated 5700 people diagnosed with MO due 
to CRVO each year in England and Wales (Royal College of 
Ophthalmologists) were treated with bevacizumab instead 
of aflibercept, the NHS would save £31,692,000 within 
1 year (£25,906,500 if treated with bevacizumab instead of 
ranibizumab). Other healthcare systems would also see cost 
savings, provided the cost per injection for bevacizumab is 
Table 4  Model-based analysis: disaggregated costs (base case)
Costs, £ (95% CI) Ranibizumab Aflibercept Bevacizumab
1. Treatment costs
 a. Study eye intervention costs 11,785 (11,387–12,184) 17,156 (16,582–17,730) 634 (614–654)
 b. Study eye central subfield thickness 
examination and visit costs
5427 (5351–5503) 5372 (5299–5444) 5622 (5542–5701)
 c. Non-study eye drug costs 771 (750–792) 1051 (1021–1081) 40 (39–41)
 d. Non-study eye central subfield thick-
ness examination and visit costs
268 (262–274) 249 (242–255) 276 (270–282)
2. Disease management costs 9588 (9049–10,127) 10,058 (9435–10,681) 9283 (8807–9759)
3. Ocular adverse event costs 1322 (1238–1405) 109 (101–117) 1392 (1301–1483)
4. Blindness costs 1065 (918–1212) 1031 (886–1176) 1107 (957–1257)
Total costs 30,226 (29,386–31,066) 35,026 (33,990–36,062) 18,353 (17,782–18,925)
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lower than aflibercept and ranibizumab. Wider arguments 
are made for and against the use of bevacizumab for oph-
thalmologic indications in the NHS [37, 38].
Our base-case analysis for the bevacizumab injection was 
based on separating the larger vial into prefilled syringes (as 
used in the LEAVO study), i.e. compounding, at a cost of 
£28. In clinical practice, if there are additional costs associ-
ated with the compounding, then the total costs of bevaci-
zumab will increase. However, the scenario analysis found 
that even assuming a full vial of bevacizumab using the list 
price, bevacizumab was still significantly cheaper than and 
dominated ranibizumab and aflibercept.
It is possible that patients in clinical practice may receive 
fewer injections than in LEAVO. For example, the real-
world LUMINOUS study found that the mean number of 
ranibizumab injections in patients with CRVO was 4.2 at 
month 12 and 5.6 at month 24 [39]. These are somewhat 
lower than the mean number of ranibizumab injections at 
similar time points in LEAVO: 8.1 at week 52 and 11.8 at 
week 100 [18]. Assuming a similar reduction in injection 
frequency for ranibizumab, aflibercept and bevacizumab, we 
would expect the total costs of each intervention to be lower 
and therefore the cost saving associated with bevacizumab 
to be lower. However, reducing visits and treatments may 
not necessarily be appropriate. Based on a careful second 
year follow-up and anti-vascular endothelial growth factor 
therapy if reinjection criteria were met, patients in LEAVO 
maintained initial visual acuity gains at 2 years. This was not 
the case in certain trials such as COPERNICUS [40] where 
in principle, a 3-monthly follow-up in the second year led 
to visual acuity losses, nor can it definitely be concluded in 
real-world data such as LUMINOUS, where the drop-out 
rate by 2 years in the treatment-naïve CRVO cohort was 
high [39], making interpretation of visual acuity outcomes 
difficult. Therefore, care must be taken to ensure that reduc-
ing visit and injection frequency does not compromise visual 
acuity outcomes.
4.2  Validation
The 100-week scenario analysis in the model gives simi-
lar results to the within-trial analysis, suggesting that the 
long-term model is valid for estimating short-term costs 
and QALYs. To validate the extrapolation, we compared 
our results to models for aflibercept and ranibizumab 
in CRVO. Evidence submitted by Novartis for NICE’s 
appraisal of ranibizumab considered a 15-year time hori-
zon and reported lower mean survival (12.3 years), QALYs 
(7.55 using VFQ-UI) and costs (£26,327) than our model, as 
would be expected for a shorter time horizon [41]. Most of 
the results of Bayer’s cost-effectiveness analysis for NICE’s 
appraisal of aflibercept are redacted, but the QALY gain for 
aflibercept vs ranibizumab over a lifetime was reported to 
be 0.054 using EQ-5D [42]—our model gave results of a 
similar magnitude.
A recent systematic review of the three interventions 
across other retinal conditions identified two large US tri-
als that provided evidence that ranibizumab and aflibercept 
are not cost effective compared to bevacizumab in other 
retinal conditions [43]. Additionally, a large UK-based 
trial in age-related macular degeneration was inconclusive 
in comparing bevacizumab to ranibizumab using BCVA 
[44]. The trial found that ranibizumab is not cost effec-
tive compared to bevacizumab owing to its substantially 
larger costs and small QALY gain [45]. The cost-effec-
tiveness results for MO in our study are consistent with 
these findings.
Our assumption that LEAVO is representative of the 
patient population in England appears valid when consider-
ing that LEAVO was conducted entirely in UK settings, and 
when comparing against the international real-world LUMI-
NOUS study, which had a similar baseline age (LEAVO: 
69.1, LUMINOUS: 69.7), proportion of female patients 
(LEAVO: 48.8, LUMINOUS: 41.5) and baseline BCVA 
(LEAVO: 54.1, LUMINOUS: 44.7) [18, 39]. Although base-
line BCVA is higher in LEAVO than LUMINOUS, a pre-
specified subgroup analysis in LEAVO found no statistically 
significant differences across subgroups in baseline BCVA 
score for changes in BCVA letter scores from baseline to 
100 weeks [18].
4.3  Strengths and Limitations
Our study used a within-trial and model-based analysis to 
estimate the cost effectiveness of the three interventions, 
with the same findings. Both methods followed best practice 
guidelines [20, 21, 24, 46]. We avoided arbitrarily catego-
rising BCVA scores into health states, thus we were able 
to model small changes in visual acuity, and incorporated 
heterogeneity by modelling patients with different baseline 
characteristics while preserving the relationship between 
different characteristics. We were able to model the study 
and non-study eye separately and use both to predict utility 
and resource use.
Using patient-level data from LEAVO enabled us to pre-
dict BCVA and CST change that accounted for patient-level 
characteristics as well as trends over time. Our mappings 
used flexible models to account for the unique distributions 
of utility data. While LEAVO provided rich data for the 
study period, health economics data (comparable by arm) 
were missing. Resource use questionnaires are also vul-
nerable to recall bias. In LEAVO, resource use marginally 
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contributed to the overall total cost in each arm; therefore, 
it is unlikely to change the health economic conclusions. 
Additionally, the multiple imputation model suggested that 
the results were consistent with those from the complete 
case analysis.
LEAVO was limited to a duration of 100 weeks and 
thus did not provide long-term data on the effectiveness or 
safety. We identified limited long-term data in a systematic 
review that we could use to populate the model. This led to 
uncertainty in the long-term extrapolations of effectiveness, 
withdrawals, adverse events and development of MO in the 
non-study eye. For natural history, we relied on a study of 
the general population from over 20 years ago (Beaver Dam 
Study) as newer studies did not provide numerical data [47].
5  Conclusions
Although LEAVO could not demonstrate bevacizumab to 
be non-inferior to ranibizumab and aflibercept in terms of 
visual acuity gain, our analysis suggests that bevacizumab 
was the most cost-effective intervention, in terms of cost per 
QALY using VFQ-UI or EQ-5D, for the treatment of MO 
due to CRVO. While patients, funders and ophthalmologists 
should be fully informed about the clinical efficacy of beva-
cizumab compared to aflibercept or ranibizumab, its routine 
use for MO secondary to CRVO would lead to substantial 
cost savings. Whether this would lead to small health gains 
or losses depends on the outcome measure used to determine 
HRQoL.
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